Deutsche Bank AG Has $5.30 Million Stock Position in Progyny, Inc. $PGNY

Deutsche Bank AG lowered its holdings in Progyny, Inc. (NASDAQ:PGNY - Free Report) by 36.9% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 237,403 shares of the company's stock after selling 138,954 shares during the quarter. Deutsche Bank AG owned 0.28% of Progyny worth $5,304,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Natixis acquired a new stake in shares of Progyny during the 4th quarter worth approximately $69,000. GAMMA Investing LLC boosted its stake in Progyny by 233.9% in the 1st quarter. GAMMA Investing LLC now owns 5,379 shares of the company's stock valued at $120,000 after buying an additional 3,768 shares in the last quarter. State of Wyoming boosted its stake in Progyny by 98.2% in the 4th quarter. State of Wyoming now owns 12,376 shares of the company's stock valued at $213,000 after buying an additional 6,132 shares in the last quarter. Cerity Partners LLC acquired a new stake in Progyny in the 4th quarter valued at $229,000. Finally, XTX Topco Ltd acquired a new stake in Progyny in the 1st quarter valued at $241,000. Institutional investors and hedge funds own 94.93% of the company's stock.

Progyny Stock Up 3.8%

PGNY stock opened at $23.40 on Monday. The company has a market cap of $2.01 billion, a P/E ratio of 39.66, a PEG ratio of 2.29 and a beta of 1.32. Progyny, Inc. has a twelve month low of $13.39 and a twelve month high of $26.76. The business has a fifty day moving average of $22.41 and a 200-day moving average of $22.16.

Progyny (NASDAQ:PGNY - Get Free Report) last released its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing analysts' consensus estimates of $0.42 by ($0.23). The firm had revenue of $332.87 million for the quarter, compared to the consensus estimate of $315.70 million. Progyny had a return on equity of 10.69% and a net margin of 4.28%. The company's revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.17 EPS. As a group, equities research analysts anticipate that Progyny, Inc. will post 0.6 earnings per share for the current fiscal year.

Insiders Place Their Bets

In related news, Director Cheryl Scott sold 2,675 shares of Progyny stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $22.07, for a total transaction of $59,037.25. Following the completion of the sale, the director directly owned 14,112 shares of the company's stock, valued at $311,451.84. The trade was a 15.93% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Kevin K. Gordon sold 2,500 shares of Progyny stock in a transaction on Monday, August 11th. The stock was sold at an average price of $22.04, for a total value of $55,100.00. Following the sale, the director directly owned 12,501 shares of the company's stock, valued at approximately $275,522.04. This trade represents a 16.67% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders own 9.40% of the company's stock.

Analysts Set New Price Targets

Several brokerages recently commented on PGNY. Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $28.00 price target (up previously from $26.00) on shares of Progyny in a research note on Friday, August 8th. Canaccord Genuity Group decreased their price target on Progyny from $23.00 to $21.00 and set a "hold" rating on the stock in a research note on Monday, May 12th. Leerink Partnrs raised Progyny from a "hold" rating to a "strong-buy" rating in a research note on Tuesday, July 8th. Raymond James Financial set a $28.00 price target on Progyny in a research note on Friday, August 8th. Finally, Wall Street Zen raised Progyny from a "hold" rating to a "buy" rating in a research note on Saturday, July 26th. Four investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $24.90.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.

Want to see what other hedge funds are holding PGNY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Progyny, Inc. (NASDAQ:PGNY - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.